Biocon Breaks New Ground: Launches Affordable GLP-1 Powerhouse Liraglutide in Netherlands

Biocon's Liraglutide (6 mg/ml solution in pre-filled pens) enters the Netherlands following EU Decentralized Procedure approval and prior UK success. This vertically integrated generic rivals Novo Nordisk's Victoza® (diabetes) and Saxenda® (weight loss), positioning Biocon as a generics leader in complex peptides. The move expands its European footprint after MHRA nods in the UK.​

Key Highlights

Pioneering Entry: First direct Biocon launch of Liraglutide in an EU country, building on UK brands Liraglutide Biocon and Biolide.​

Dual Indications: Diavorin® for Type-2 diabetes; Vobexoryn® for obesity alongside diet and exercise.​

Strategic Milestone: Follows India approval (June 2025) and partnerships like Zentiva for EU distribution.​

Market Impact: Boosts affordable GLP-1 access in high-demand Europe, with plans for US and more regions.​

Outlook

This launch underscores Biocon's GLP-1 prowess, potentially driving revenue as obesity therapies boom. Shares may see positive momentum amid India's market focus.​

Sources: NSE India Archives, Business Upturn